List view / Grid view
HIV (Human Immunodeficiency Virus)
Efficiency of Gilead Science’s long-term HIV treatment option with a high barrier to resistance has been further demonstrated in real-world data based on three-year study follow up.
The first long-acting injectable PrEP option proven superior to daily oral FTC/TDF in reducing HIV acquisition, has been approved in the European Union (EU).
The first fixed dose combination (FDC) formulation containing dolutegravir that is suitable for certain paediatric HIV patients globally, has been deemed safe and effective by US researchers.
Sublicence agreements signed by the Medicines Patent Pool (MPP) and three generic manufacturers could enable millions to access a long-acting HIV medicine.
The world‘s first international trial into second-line HIV therapy has shown two simplified treatments are at least as effective as standard of care.
HIV patients received real-time antiretroviral dosage data from an innovative edible sensor in a clinical trial.